Regeneron Pharmaceuticals Stock News

U.S. President ​Donald Trump's administration ‌is planning to ​announce ​a new round ⁠of ​drug-pricing agreements ​with midsize biotech companies on ​Monday, ​Bloomberg News reported ‌on ⁠Wednesday, citing people familiar to ​the ​matter.

The ​U.S. FDA on Wednesday approved Regeneron's experimental drug for a ‌rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability

BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #biosimilar--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg, Used to Treat Various Types of Ophthalmology Conditions.

Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the recipients of the 2026 Regeneron Prize for Creative Innovation (“the Regeneron Prize”).

Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by ​strong demand for its eczema drug Dupixent and ‌a high-dose version of its eye drug Eylea.

TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update.